(No ratings)
Dr. Matthew M. Heeney, MD is a physician provider in Boston, MA specializing in physician and pediatric hematology/oncology. He graduated from University of Calgary in 1995 and has 31 years of experience. Dr. Matthew M. Heeney, MD is affiliated with Dana-Farber Cancer Institute and Boston Medical Center.
Dr. Matthew M. Heeney, MD graduated from University of Calgary in 1995. He completed residency at The Montreal Children's Hospital. He is certified by the Board Certification: Pediatric Hematology/Oncology and Pediatrics and has a state license in Massachusetts.
Medical School: University of Calgary (1995)
Residency: The Montreal Children's Hospital
Board Certification: Board Certification: Pediatric Hematology/Oncology and Pediatrics
Licensed In: Massachusetts
Dr. Matthew M. Heeney, MD appears to accept the following insurance providers: MultiPlan (Beech Street): Medicare Advantage Private FFS Network, MultiPlan (PPO Network Company): Complementary Network, United Healthcare: Commercial & SCO, Unicare: Commonwealth Indemnity Plan (formerly GIC), Humana, Cigna: HealthSource Preferred Managed Worker's Comp, Tufts Health Public Plans (THPP): MassHealth, HPHC: HMO, MultiPlan (Beech Street): MA PPO Network, Kaiser, Fallon: Senior Plan, CCA: SCO Primary Care, Neighbborhood: Commonwealth Choice, Neighbborhood: ACO, Aetna: QPOS, Neighbborhood: Commonwealth Care, Fallon: Major Medical/Health & Life Assurance Company Programs, Aetna: ElectChoice, Fallon: Select Care, CCA: Inpatient Services Program, BCBSMA: Indemnity, Aetna: Aetna Choice POS II, CCA: OneCare, BCBSMA: HMO Blue, Fallon: Flex Care Select, Aetna: Managed Choice POS, Senior Whole Health: SCO, BMC Healthnet: MassHealth, Neighbborhood: CarePlus, BMC Healthnet: ACO & Senior Care Options, Neighborhood PACE, Aetna: National Advantage, Fallon: Preferred Care, Uphams Elder Svc Plan: PACE - Elder Service Providers, BCBSMA: Preferred Provider Arrangement, Neighbborhood: CMA, Health Plans Inc., BMC Healthnet: Commonwealth Choice, Neighbborhood: MassHealth, Fallon: Senior Plan Preferred, Chickering Claims Administrators: Student Health Plan, CCA: SCO, Aetna: HMO, Aetna: Open Choice PPO, VA Choice, BMC Healthnet: QHP, Neighbborhood: Commercial and Aetna: Aetna Select.
According to our sources, Dr. Matthew M. Heeney, MD accepts the following insurance providers:
Dr. Matthew M. Heeney, MD does not have any reviews yet, be the first to leave a review of Dr. Matthew M. Heeney, MD here: Leave a Review
(No ratings)
These charts describe general payments received by Dr. Matthew M. Heeney, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
| Novartis Pharmaceuticals Corporation |
$50,663
CRIZANLIZUMAB $15,269 |
ADAKVEO $12,667 |
Exjade $980 |
$21,747 |
|
|---|---|---|---|---|---|
| AstraZeneca AB |
$49,282
BRILINTA $14,854 |
$34,428 |
|||
| Vertex Pharmaceuticals Incorporated |
$35,828
$35,828 |
||||
| Eli Lilly and Company |
$22,964
Effient $15,890 |
$7,074 |
|||
| Octapharma USA, Inc. |
$18,960
$18,960 |
||||
| Other |
$48,893
OXBRYTA $14,790 |
BRILINTA $5,360 |
DOPTELET $4,248 |
PYRUKYND $3,392 |
$21,102 |
| Consulting Fee | $122,811 |
|---|---|
| Travel and Lodging | $69,658 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $12,565 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,998 |
| Food and Beverage | $5,058 |
| Other | $4,500 |
Dr. Matthew M. Heeney, MD has received 88 research payments totaling $1,098,801.
Matthew Heeney, MD, is board certified in pediatrics and pediatric hematology/oncology. He is the Associate Chief for Hematology in the Division of Hematology/Oncology and the Director of the Sickle Cell Program in Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dr Heeney's research interests are focused on sickle cell disease and congenital disorders of iron metabolism. The goals of Dr Heeney's research include improving the understanding of the pathophysiology and treatment of sickle cell anemia through clinical investigation and elucidating the genetic basis of iron homeostasis and its role in human disease.